Renier J. Brentjens, MD, PhD, from Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of CAR-modified T cells for the treatment of solid tumors.
Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, discusses the potential efficacy of chimeric antigen receptor (CAR)-modified T cells for the treatment of solid tumors.
Moving CAR-modified T cells to other types of cancer first requires the identification of antigens on tumor cells that can be safely targeted. Even when an optimal target is selected, the tumor microenvironment must be considered. Brentjens says that it is clear that solid tumors are able to recruit immunosuppressive cells and factors that could inhibit the efficacy of CAR-modified T cells.
After identifying proper targets, researchers and physicians must build a better T cell that can overcome the hostile environment of a solid tumor.
Finally, there is a need to develop clinically relevant mouse models before injecting into humans. The oncology community, Brentjens says, needs to be careful not to rush this technology into patients.Necessary steps to move CAR-modified T cells into solid tumors:
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Deciding Factors for Front-Line Therapy in Metastatic RCC
April 17th 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on what factors influence physician decision making for frontline therapy in patients with metastatic renal cell carcinoma in the first article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen